Valuation : Monopar Therapeutics Inc.

Market Cap 740M 638M 604M 547M 1.03B 70.7B 1.03B 7.17B 2.76B 35.97B 2.78B 2.72B 114B P/E 2026 *
-44.2x
P/E 2027 * -44x
Enterprise Value 621M 535M 507M 459M 862M 59.36B 866M 6.02B 2.32B 30.2B 2.33B 2.28B 95.43B EV / Sales 2026 *
-
EV / Sales 2027 * 21.1x
Free-Float
76.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.27%
1 week-6.21%
Current month-1.49%
1 month-0.14%
3 months+84.47%
6 months+82.67%
Current year+68.85%
1 week 108.84
Extreme 108.84
117.61
1 month 104.48
Extreme 104.48
124.27
Current year 50.07
Extreme 50.07
124.82
1 year 46.89
Extreme 46.89
124.82
3 years 1.37
Extreme 1.3695
124.82
5 years 1.37
Extreme 1.3695
124.82
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 01/12/2014
Director of Finance/CFO 54 03/03/2025
Chief Tech/Sci/R&D Officer 64 01/09/2026
Director TitleAgeSince
Director/Board Member 42 01/12/2014
Chairman 73 01/12/2014
Director/Board Member 84 01/04/2017
Date Insider Type Main position Quantity % Market Cap. Importance
26/8/26 Exercice

Chief Technology Officer

2,761 0.0412%
26/8/26 Sell

Director

-4,090 0.0611%
26/8/26 Exercice

Director

12,270 0.1832%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-6.21%+124.01%+3,488.61% 740M
-0.71%-6.35%-2.99%+9.37% 45.48B
+0.21%-2.98%+337.74%+520.30% 43.68B
+1.74%-2.24%+39.82%+20.85% 43.09B
+1.38%-3.28%+6.84%+73.19% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+108.58% 16.4B
-0.31%-2.78%+10.78%+30.20% 14.24B
+1.93%-3.55%+82.00%+36.66% 13.28B
Average +0.47%-3.50%+69.66%+480.84% 26.55B
Weighted average by Cap. +0.41%-3.50%+74.71%+134.89%

Financials

2026 *2027 *
Net sales - 28.26M 24.35M 23.05M 20.9M 39.2M 2.7B 39.4M 274M 105M 1.37B 106M 104M 4.34B
Net income -21.46M -18.49M -17.51M -15.87M -29.78M -2.05B -29.93M -208M -79.97M -1.04B -80.61M -78.84M -3.3B -26.62M -22.93M -21.71M -19.68M -36.92M -2.54B -37.11M -258M -99.17M -1.29B -99.96M -97.77M -4.09B
Net Debt -119M -102M -96.89M -87.82M -165M -11.35B -166M -1.15B -442M -5.77B -446M -436M -18.24B -145M -125M -118M -107M -201M -13.81B -202M -1.4B -539M -7.03B -543M -531M -22.2B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
-
Date Price Change Volume
11/09/26 US$110.26 +0.27% 90,261
10/09/26 US$109.96 -2.15% 94,154
09/09/26 US$112.38 -1.75% 111,398
08/09/26 US$114.38 -2.71% 103,870
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
110.26USD
Average target price
127.62USD
Spread / Average Target
+15.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!